Christopher Sjöwall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7612358/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
2	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 736-743.	0.9	135
3	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes and Immunity, 2011, 12, 100-109.	4.1	113
4	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 1607-1613.	0.9	103
5	Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. European Journal of Human Genetics, 2013, 21, 994-999.	2.8	90
6	Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis. PLoS ONE, 2013, 8, e84450.	2.5	88
7	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 1544-1549.	0.9	86
8	Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. Arthritis Research and Therapy, 2015, 17, 3.	3.5	84
9	Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Research, 2004, 6, R87.	2.0	82
10	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 343-351.	5.8	80
11	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the Rheumatic Diseases, 2021, 80, 1086-1093.	0.9	79
12	Interferonâ€Î± mediates suppression of Câ€reactive protein: Explanation for muted Câ€reactive protein response in lupus flares?. Arthritis and Rheumatism, 2009, 60, 3755-3760.	6.7	78
13	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 363-369.	0.9	76
14	Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. Lupus, 2015, 24, 569-581.	1.6	64
15	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. Journal of Immunological Methods, 2018, 459, 11-19.	1.4	64
16	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. Human Genetics, 2019, 138, 141-150.	3.8	63
17	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1363-1370.	0.9	60
18	Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis, PLoS ONE, 2016, 11, e0165373.	2.5	60

#	Article	IF	CITATIONS
19	Autoantibodies to C-reactive Protein is a Common Finding in SLE, but not in Primary Sj¶gren's Syndrome, Rheumatoid Arthritis or Inflammatory Bowel Disease. Journal of Autoimmunity, 2002, 19, 155-160.	6.5	58
20	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. Journal of Rheumatology, 2015, 42, 817-825.	2.0	57
21	Sex differences in clinical presentation of systemic lupus erythematosus. Biology of Sex Differences, 2019, 10, 60.	4.1	55
22	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Populationâ€Based Study of Maternal and Fetal Outcomes in SLE and Preâ€6LE. Arthritis Care and Research, 2016, 68, 988-994.	3.4	54
23	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Scientific Reports, 2017, 7, 6236.	3.3	54
24	The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable. Lupus, 2019, 28, 778-782.	1.6	52
25	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Annals of the Rheumatic Diseases, 2019, 78, 320-327.	0.9	50
26	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine, 2020, 7, 316.	2.6	50
27	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clinica Chimica Acta, 2007, 378, 13-23.	1.1	48
28	Association between genetic variants in the tumour necrosis factor/lymphotoxin α/lymphotoxin β locus and primary Sjögren's syndrome in Scandinavian samples. Annals of the Rheumatic Diseases, 2012, 71, 981-988.	0.9	47
29	Association of Genes in the <scp>NF</scp> â€₽B Pathway with Antibodyâ€Positive Primary Sjögren's Syndrome. Scandinavian Journal of Immunology, 2013, 78, 447-454.	2.7	45
30	No Evidence of Pathogenic Involvement of Cathelicidins in Patient Cohorts and Mouse Models of Lupus and Arthritis. PLoS ONE, 2014, 9, e115474.	2.5	45
31	Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open, 2013, 3, e003608.	1.9	44
32	Complement Opsonization of HIV-1 Results in Decreased Antiviral and Inflammatory Responses in Immature Dendritic Cells via CR3. Journal of Immunology, 2014, 193, 4590-4601.	0.8	44
33	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Translational Research, 2013, 162, 287-296.	5.0	43
34	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskeletal Disorders, 2015, 16, 188.	1.9	43
35	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Research and Therapy, 2016, 18, 289.	3.5	43
36	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1063-1069.	0.9	41

CHRISTOPHER SJöWALL

#	Article	IF	CITATIONS
37	Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. Frontiers in Pharmacology, 2019, 10, 82.	3.5	40
38	Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus. Journal of Autoimmunity, 2004, 22, 315-323.	6.5	39
39	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Research and Therapy, 2009, 11, R188.	3.5	39
40	Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open, 2016, 6, e007769.	1.9	39
41	Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology, 2018, 57, 1400-1407.	1.9	39
42	Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome. Frontiers in Immunology, 2019, 10, 1686.	4.8	39
43	Cytokine induction by circulating immune complexes and signs ofin-vivocomplement activation in systemic lupus erythematosus are associated with the occurrence of anti-SjA¶gren's syndrome A antibodies. Clinical and Experimental Immunology, 2007, 147, 513-520.	2.6	38
44	Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. Cell Reports, 2016, 16, 2928-2939.	6.4	38
45	Common Genetic Variations in the NALP3 Inflammasome Are Associated with Delayed Apoptosis of Human Neutrophils. PLoS ONE, 2012, 7, e31326.	2.5	37
46	Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. Journal of Rheumatology, 2008, 35, 1994-2000.	2.0	37
47	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP–C1q interaction. Biochemical and Biophysical Research Communications, 2007, 352, 251-258.	2.1	35
48	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity, 2013, 46, 205-214.	2.6	35
49	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Annals of the Rheumatic Diseases, 2021, 80, 109-117.	0.9	35
50	Association of Serum Câ€Reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferonâ€î± and a Câ€Reactive Protein Gene Variant. Arthritis and Rheumatology, 2014, 66, 1568-1573.	5.6	30
51	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 254-261.	0.9	30
52	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. Clinical and Experimental Immunology, 2020, 199, 245-254.	2.6	29
53	Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility. Genes and Immunity, 2013, 14, 217-222.	4.1	28
54	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. Journal of Hepatology, 2014, 60, 1259-1267.	3.7	28

#	Article	IF	CITATIONS
55	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Translational Research, 2015, 165, 658-666.	5.0	28
56	Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scandinavian Journal of Rheumatology, 2014, 43, 428-430.	1.1	27
57	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 338.	3.5	27
58	Soluble urokinase plasminogen activator receptor—A valuable biomarker in systemic lupus erythematosus?. Clinica Chimica Acta, 2015, 444, 234-241.	1.1	27
59	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
60	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. Journal of Clinical Medicine, 2021, 10, 5837.	2.4	27
61	Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?. Arthritis Care and Research, 2014, 66, 1710-1717.	3.4	26
62	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. Lupus, 2016, 25, 864-872.	1.6	26
63	Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. Clinical and Experimental Immunology, 2017, 189, 372-382.	2.6	26
64	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2020, 21, 3463.	4.1	26
65	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. Frontiers in Immunology, 2020, 11, 622326.	4.8	26
66	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Human Immunology, 2012, 73, 382-388.	2.4	25
67	Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus, 2017, 26, 1333-1338.	1.6	25
68	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Seminars in Arthritis and Rheumatism, 2016, 45, 684-690.	3.4	23
69	Neutrophil Extracellular Traps (NETs) in the Cerebrospinal Fluid Samples from Children and Adults with Central Nervous System Infections. Cells, 2020, 9, 43.	4.1	23
70	Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus. Trends in Molecular Medicine, 2019, 25, 826-835.	6.7	22
71	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Lupus, 2019, 28, 1261-1272.	1.6	22
72	Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. Frontiers in Immunology, 2021, 12, 756941.	4.8	22

CHRISTOPHER SJöWALL

#	Article	IF	CITATIONS
73	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opinion on Biological Therapy, 2018, 18, 911-920.	3.1	21
74	Câ€reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. Immunology and Cell Biology, 2008, 86, 466-474.	2.3	20
75	Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology, 2017, 56, kew459.	1.9	19
76	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. Lupus Science and Medicine, 2017, 4, e000225.	2.7	18
77	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clinica Chimica Acta, 2009, 400, 128-131.	1.1	17
78	Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 <i>in vitro</i> . Clinical and Experimental Immunology, 2017, 189, 83-91.	2.6	17
79	Beware of Antibodies to Dietary Proteins in "Antigen-specific―Immunoassays! Falsely Positive Anticytokine Antibody Tests Due to Reactivity with Bovine Serum Albumin in Rheumatoid Arthritis (The) Tj ETQq1	120078431	l 4 6gBT /Ove
80	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clinical and Experimental Immunology, 2018, 194, 27-38.	2.6	16
81	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2019, 21, 259.	3.5	16
82	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	3.4	16
83	Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells. Journal of Virology, 2016, 90, 4939-4950.	3.4	15
84	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
85	The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis. Frontiers in Medicine, 2021, 8, 807996.	2.6	15
86	<i>De novo</i> lupus nephritis during treatment with belimumab. Rheumatology, 2021, 60, 4348-4354.	1.9	14
87	Resistin is Associated with Breach of Tolerance and Antiâ€nuclear Antibodies in Patients with Hepatobiliary Inflammation. Scandinavian Journal of Immunology, 2011, 74, 463-470.	2.7	13
88	Long-term outcomes of destructive seronegative (rheumatoid) arthritis – description of four clinical cases. BMC Musculoskeletal Disorders, 2016, 17, 246.	1.9	13
89	Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus. Journal of Immunology Research, 2018, 2018, 1-9.	2.2	13
90	SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. Frontiers in Immunology, 2021, 12, 724047.	4.8	13

CHRISTOPHER SJĶWALL

#	Article	IF	CITATIONS
91	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open, 2021, 7, e001987.	3.8	13
92	Uptake of rheumatology biosimilars in the absence of forced switching. Expert Opinion on Biological Therapy, 2018, 18, 499-504.	3.1	12
93	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. European Journal of Human Genetics, 2019, 27, 432-441.	2.8	12
94	Adverse Pregnancy Outcomes after Multi-Professional Follow-Up of Women with Systemic Lupus Erythematosus: An Observational Study from a Single Centre in Sweden. Journal of Clinical Medicine, 2020, 9, 2598.	2.4	12
95	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 688753.	4.8	12
96	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. Frontiers in Immunology, 2021, 12, 722118.	4.8	12
97	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD Open, 2022, 8, e002099.	3.8	12
98	Active NET formation in Libman–Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. Autoimmunity, 2018, 51, 310-318.	2.6	11
99	High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. Frontiers in Medicine, 2020, 7, 581336.	2.6	11
100	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	4.8	11
101	Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. Clinical and Experimental Immunology, 2020, 203, 22-31.	2.6	11
102	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 1183-1189.	0.9	10
103	Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus, 2020, 29, 625-630.	1.6	9
104	Variants in BANK1 are associated with lupus nephritis of European ancestry. Genes and Immunity, 2021, 22, 194-202.	4.1	9
105	Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. Arthritis Research and Therapy, 2022, 24, .	3.5	9
106	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. Nephrology Dialysis Transplantation, 2014, 30 Suppl 1, i23-30.	0.7	8
107	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. Frontiers in Immunology, 2020, 11, 607166.	4.8	8
108	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. Lupus Science and Medicine, 2021, 8, e000463.	2.7	8

#	Article	IF	CITATIONS
109	CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus. Current Rheumatology Reviews, 2005, 1, 81-89.	0.8	7
110	Synthesis of an Array of Triple-Helical Peptides from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid Arthritis. ACS Chemical Biology, 2020, 15, 2605-2615.	3.4	7
111	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. Annals of the Rheumatic Diseases, 2021, 80, 404-406.	0.9	7
112	Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. Frontiers in Medicine, 2021, 8, 722758.	2.6	7
113	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. Rheumatology, 2022, 61, 3596-3605.	1.9	7
114	Anti-CRP Autoantibody Levels Correlate with Disease Activity in Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 2005, 35, 65-66.	3.4	6
115	Contributions of de novo variants to systemic lupus erythematosus. European Journal of Human Genetics, 2021, 29, 184-193.	2.8	6
116	Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome. Scandinavian Journal of Rheumatology, 2021, 50, 1-10.	1.1	6
117	IgA rheumatoid factor in rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1617-1626.	2.3	6
118	Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives. Clinical and Experimental Immunology, 2020, 199, 143-149.	2.6	5
119	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110138.	1.6	5
120	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. Rheumatology, 2020, 59, 979-987.	1.9	4
121	Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-l Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. Frontiers in Medicine, 2021, 8, 646846.	2.6	4
122	Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity. Lupus Science and Medicine, 2021, 8, e000471.	2.7	4
123	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. Journal of Clinical Medicine, 2021, 10, 3820.	2.4	4
124	Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis. Clinical Rheumatology, 2022, 41, 1561-1568.	2.2	4
125	Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement. Scandinavian Journal of Rheumatology, 2015, 44, 337-339.	1.1	3
126	Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature. Frontiers in Medicine, 2021, 8, 661101.	2.6	3

#	Article	IF	CITATIONS
127	S4D:5â€Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus erythematosus. , 2018, , .		2
128	P137â€De novo lupus nephritis during belimumab treatment. , 2020, , .		2
129	Pentraxinâ€3 detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. Apmis, 2021, 129, 304-313.	2.0	2
130	Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 265-70.	1.1	2
131	Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Annals of the Rheumatic Diseases, 2022, 81, 1379-1384.	0.9	2
132	Affected Microcirculation and Vascular Hemodynamics in Takayasu Arteritis. Frontiers in Physiology, 0, 13, .	2.8	2
133	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. Arthritis and Rheumatology, 2017, 69, 1707-1709.	5.6	1
134	207â€A high genetic risk score is associated with early disease onset, organ damage and decreased survival in systemic lupus erythematosus. , 2019, , .		1
135	P86â€The NCF1–339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
136	Correspondence on â€~Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219296.	0.9	1
137	Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. Frontiers in Neurology, 2021, 12, 645298.	2.4	1
138	POS0601â€DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIR USERS OF EACH MOLECULE. Annals of the Rheumatic Diseases, 2021, 80, 535.2-535.	ST.9	1
139	POS1169â€IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENT WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. Annals of the Rheumatic Diseases, 2021, 80, 864-865.	S 0.9	1
140	A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity. Scandinavian Journal of Rheumatology, 2021, , 1-3.	1.1	1
141	OPO362â€Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. , 2018, , .		1
142	Comment on â€~Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge': reply. Scandinavian Journal of Rheumatology, 2021, , 1-2.	1.1	1
143	Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 1360-1368.	0.8	1
144	Variation of Complement Protein Levels in Maternal Plasma and Umbilical Cord Blood during Normal Pregnancy: An Observational Study. Journal of Clinical Medicine, 2022, 11, 3611.	2.4	1

CHRISTOPHER SJöWALL

#	Article	IF	CITATIONS
145	Autoantibodies Associated with Autoimmune Liver Diseases in a Healthy Population: Evaluation of a Commercial Immunoblot Test. Diagnostics, 2022, 12, 1572.	2.6	1
146	Tu-P10:452 C-reactive protein inhibit complement-mediated platelet activation suggesting a protective role in atherogenesis. Atherosclerosis Supplements, 2006, 7, 284.	1.2	0
147	Dr. Skogh, <i>et al,</i> reply. Journal of Rheumatology, 2009, 36, 1834-1834.	2.0	0
148	A3.7â€No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis. Annals of the Rheumatic Diseases, 2014, 73, A44.2-A45.	0.9	0
149	THU0042â€Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. Annals of the Rheumatic Diseases, 2014, 73, 191.1-191.	0.9	Ο
150	FRI0172â€Utility of Swedish Register Data in Classifying Systemic Lupus. Annals of the Rheumatic Diseases, 2014, 73, 444.2-444.	0.9	0
151	THU0345â€Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and β2-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 312.1-312.	0.9	Ο
152	OP0189â€Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 128.2-128.	0.9	0
153	P1_144 Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden. Rheumatology, 2017, 56, iii88-iii88.	1.9	0
154	103â€Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. , 2017, , .		0
155	THU0652â€Assessment of biosimilars using real world data: the complexity of choosing a comparator and understanding uptake. , 2017, , .		Ο
156	THU0663â€Serum galectin-3 binding protein is a novel predictor of venous thromboembolism in patients with systemic lupus erythematosus (SLE). , 2017, , .		0
157	SAT0233â€High anti-dsdna content in sle immune complexes is associated with clinical remission following belimumab treatment. , 2017, , .		0
158	Response to: †Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?' by Bruzzese and Zullo. Annals of the Rheumatic Diseases, 2018, 77, e72-e72.	0.9	0
159	SAT0209â€A SIMPLIFIED APPROACH FOR SLE PATIENTS TO REPORT DISEASE ACTIVITY USING A REVISED VERS OF THE SWEDISH SYSTEMIC LUPUS ACTIVITY QUESTIONNAIRE. , 2019, , .	ON	0
160	12â€Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2019, , .		0
161	264â€Damage accrual in swedish systemic lupus erythematosus: secondary sjögrens syndrome is among the factors associated with increased risk. , 2019, , .		0
162	43â€The diagnostic accuracy of the 2012 SLICC and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification is comparable. , 2019, , .		0

#	Article	IF	CITATIONS
163	96â€Cerebral hemodynamics and microcirculatory function in Swedish patients with systemic lupus erythematosus. , 2019, , .		0
164	P82â€Anti-phospholipid antibodies and renal involvement are the main features associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus – a long-term longitudinal study in Southern Sweden. , 2020, , .		0
165	P23â€Longitudinal antinuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of swedish cases with recent-onset disease. , 2020, , .		0
166	P91â€The development and validation of a polygenic risk score for myocardial infarction in SLE. , 2020, , .		0
167	P89â€Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2020, , .		0
168	P106â€Pentameric, but not monomeric C-reactive protein, limits the snRNP-immune complex triggered type I interferon response: implications for lupus pathogenesis. , 2020, , .		0
169	P174â€Extended arterial ultrasound revealing increased intima media thickness and relation to impaired microcirculation in systemic lupus erythematosus. , 2020, , .		0
170	P190â€A simplified approach for patients with SLE to report disease activity using a revised version of the swedish systemic lupus activity questionnaire. , 2020, , .		0
171	O34â€Variants in <i>BANK1</i> are associated with lupus nephritis. , 2020, , .		0
172	P33â€Cytokine and autoantibody profiles during treatment with belimumab in patients with systemic lupus erythematosus. , 2020, , .		0
173	THU0196â€Do contextual factors influence survival ondrug of biosimilars in clinical practice?. , 2018, , .		0
174	AB0321â€EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1459.1-1459.	0.9	0
175	AB0400â€PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSU RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS. Annals of the Rheumatic Diseases, 2020, 79, 1499.2-1500.	S _{0.9}	0